Abstract

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-19), which has resulted in high death tolls around the world and a significant health burden. The purpose of this study is to bring attention to the early diagnosis and treatment of fungal diseases in coronavirus disease 2019 (COVID-19) patients. Materials and Methods: We searched peer-reviewed articles, reviews, surveillance reports, and clinical studies published from January 2020 to December 2023 using databases including PubMed, Scopus, and Web of Science. Results: Severely ill COVID-19 patients are at high risk for life-threatening fungal co-infections. The most prevalent is pulmonary aspergillosis, affecting up to a third of ICU patients, largely driven by corticosteroid use. Candidiasis is also common with prolonged ICU stays. Diagnosis is challenging, and treatment requires specific antifungals. Conclusion: Fungal co-infections increase COVID-19 mortality. Manage with early diagnosis, targeted antifungals, and risk factor control. Global focus on awareness, diagnostics, and antifungal stewardship is crucial. Keywords: Covid-19; Sars-cov-2; Fungal co-infection; Aspergillosis; Mucormycosis; Candidiasis.